We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Vaccination with Receptor Protein Protects Mice against AD

By LabMedica International staff writers
Posted on 12 Sep 2018
A soluble version of a protein involved in the formation of toxic amyloid plaques was shown to prevent aggregation of amyloid beta (Abeta) and slow development of Alzheimer's disease (AD) in a mouse model.

The brains of Alzheimer's disease patients have been shown to express elevated levels of Toll-like receptors (TLRs), a family of proteins on the surface of immune cells that recognize molecules released by pathogens or damaged cells and then initiate an appropriate immune response. More...
Investigators at the University of Florida (Gainesville, USA) hypothesized that a decoy receptor strategy using the external domain of select TLRs could have therapeutic potential in AD.

To test this hypothesis, the investigators injected members of an AD mouse model with AAV (Adeno-associated virus) human TLR5 external domain (sTLR5) alone or fused to the human antibody fragment, IgG4 Fc (sTLR5Fc).

Results reported in the August 29, 2018, online edition of the Journal of Experimental Medicine revealed that immunization with soluble versions of TLR5 reduced the buildup of amyloid plaques in the brains of the Alzheimer's disease model mice. In vitro, these proteins protected neurons from being killed by accumulation of toxic amyloid plaques.

Senior author Dr. Todd E. Golde, professor of neuroscience at the University of Florida, said, "By directly interacting with beta-amyloid and attenuating beta-amyloid levels in mice, the soluble TLR5 decoy receptor represents a novel and potentially safe class of immunomodulatory agents for Alzheimer's disease."

Related Links:
University of Florida


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.